IsoRay, Inc. (ISR)

ISR on American Stock Exchange

--USD
--
Price Change (% chg)

-- (--)
Prev Close
$1.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
340,134
52-wk High
$2.06
52-wk Low
$0.12

ISR

Chart for ISR

About

IsoRay, Inc. is engaged in the development of permanent seed brachytherapy in the treatment of cancers. IsoRay, Inc. has obtained clearance from the United States Food and Drug Administration (FDA) for treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular... (more)

Overall

Beta: 2.38
Market Cap (Mil.): $23.63
Shares Outstanding (Mil.): 22.94
Annual Dividend: 0.00
Yield (%): NA

Financials

  ISR Industry Sector
P/E (TTM): -- 4.05 3.76
EPS (TTM): 35.37 -- --
ROI: -42.58 2.37 2.30
ROE: -45.47 3.77 2.82
view overview for:

Isoray Q1 results

ISORAY INC : * First quarter per share loss $0.09 * First quarter sales $1.86 million * Reuters Estimates first quarter earnings per share view $-0.09, revenue view $1.88 million

08 Nov 2007

IBt '07 net not to improve given U.S. closure costs

BRUSSELS, Sept 28 (Reuters) - Belgian radiotherapy implant maker International Brachytherapy said on Friday that one-off costs of ending its loss-making U.S. presence meant it would not meet its target of improving its net result in 2007.

28 Sep 2007

RPT-IBt ends U.S. activity, plans alliance with IsoRay

BRUSSELS, Sept 27 (Reuters) - Belgian radiotherapy implant maker International Brachytherapy said on Thursday it had decided to end its loss-making activities in the U.S and eyed a strategic alliance with U.S. counterpart IsoRay .

27 Sep 2007

IBt ends U.S. activity, plans alliance with IsoRay

BRUSSELS, Sept 27 (Reuters) - Belgian radiotherapy implant maker International Brachytherapy said on Thursday it had decided to end its loss-making activities in the U.S and eyed a strategic alliance with U.S. counterpart IsoRay .

27 Sep 2007

Competitors

  Earnings  vs    Estimates

view overview for: